News stories about Arrowhead Pharmaceuticals (NASDAQ:ARWR) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arrowhead Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.1879445492269 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Zacks: Analysts Expect Arrowhead Pharmaceuticals (ARWR) Will Post Earnings of -$0.19 Per Share (americanbankingnews.com)
- What is The Actual Stock’s Value – Complete Picture in Focus – Arrowhead Pharmaceuticals (NASDAQ:ARWR) (nasdaqjournal.com)
- Form SC 13G ARROWHEAD PHARMACEUTICAL Filed by: RTW INVESTMENTS, LP (streetinsider.com)
- Analysts’ Recommendation in Spotlight – Arrowhead Pharmaceuticals (NASDAQ:ARWR) (nasdaqjournal.com)
- Investors Buy Large Volume of Arrowhead Pharmaceuticals Put Options (ARWR) (americanbankingnews.com)
Shares of ARWR stock opened at $9.53 on Friday. Arrowhead Pharmaceuticals has a 12 month low of $9.36 and a 12 month high of $9.61. The company has a market cap of $840.74 million, a price-to-earnings ratio of -20.28 and a beta of 2.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.16 and a quick ratio of 10.16.
Several research firms have recently weighed in on ARWR. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 12th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. B. Riley boosted their price objective on shares of Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Monday, February 12th. Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, February 19th. Finally, Piper Jaffray upped their target price on shares of Arrowhead Pharmaceuticals to $11.00 and gave the company an “overweight” rating in a report on Tuesday, May 8th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Arrowhead Pharmaceuticals has an average rating of “Buy” and a consensus price target of $9.00.
In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $6.73, for a total value of $134,600.00. Following the completion of the transaction, the chief operating officer now directly owns 908,356 shares in the company, valued at $6,113,235.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $7.43, for a total transaction of $743,000.00. Following the completion of the transaction, the chief executive officer now owns 2,194,789 shares of the company’s stock, valued at $16,307,282.27. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 465,000 shares of company stock valued at $3,432,350. 4.60% of the stock is owned by corporate insiders.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.